The company has identified a single-gene target for cell regeneration.
Biotechnology company Shift Bioscience has identified a novel, single-gene target for cellular regeneration.
“SB000 is well positioned as a target for next-generation, safer cellular rejuvenation therapeutics, helping us bring about a future where we have substantial control over the aging process and age-related diseases,” said Shift CEO Dr Daniel Ives.
“We are pleased to progress SB000 on to proof-of-concept studies and expect this paper to be the first in a series of publications as we uncover the previously hidden biology of cellular ageing and rejuvenation.”
SB000 can reverse cellular aging across multiple cell types without inducing pluripotency pathways seen in other approaches. The target is positioned for safer cell rejuvenation therapeutics with applications across age-driven diseases.
Current approaches to cell rejuvenation focus on the Yamanaka Factors (OSKM), a combination of genes that can be used to reverse cellular aging. These can induce pluripotency, however, which may result in tumourigenesis.
SB000 is safer than OSKM and demonstrates comparable methylome rejuvenation consistently across multiple cell types.
Shift will now conduct further studies to confirm efficacy across a broader range of disease-relevant cell types.
